Open AccessThe Genetic Polymorphism of TNF-α Associated with the Anti-TNF-α Therapy Used for COVID-19 Patients – Another Possible Approach
Author(s) -
Luciano Barreto Silva,
Guilherme Marinho Sampaio,
Rodolfo Scavuzzi Carneiro Cunha,
Caroline Isabele Félix Muniz,
Alfredo Júlio Fernandes Neto,
Hemanuelly Albuquerque dos Anjos,
Felipe Leonardo de Melo Almeida Fonseca,
Ailton Coelho de Ataíde Filho
Publication year - 2022
Publication title -
research, society and development
Language(s) - English
Resource type - Journals
ISSN - 2525-3409
DOI - 10.33448/rsd-v11i1.21576
Subject(s) - covid-19 , tumor necrosis factor alpha , medicine , polymorphism (computer science) , bioinformatics , immunology , genotype , biology , genetics , virology , gene , disease , outbreak , infectious disease (medical specialty)
Objective: This work aimed of to review the implications of anti-TNF-α therapy in COVID-19 patients associated with the genetic polymorphism (TNF-α polymorphisms in the region-308) of this pertinent cytokine Methodology: Electronic searches were carried out on PUBMED Central, BVS/BIREME, Web of Science and The Cochrane Library with the aid of key-words. Results: Twenty-six articles were collected. Anti-TNF-α therapy was interpreted and evaluated. Conclusions: Although scarce information is available in the current literature, anti- TNF-α therapy seems to be a viable clinical approach for hospitalized COVID-19 patients who do not need oxygen supply. The genetic polymorphisms, although relevant, may be useful for further researched to assess the clinical response in different research groups.